Human Wild-Type α-Synuclein Drives Progressive Tau Pathology in a Disease-Relevant Mouse Model of Synucleinopathy

Topic: Disease mechanisms in lab and animal studies

Tau pathology, characterized by the aberrant aggregation and accumulation of tau in neurons and glial cells, plays a critical role in the onset and progression of multiple neurodegenerative diseases. Although synucleinopathies such as Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are primarily defined by intracytoplasmic inclusions of α-Synuclein (α-Syn), they frequently exhibit substantial tau co-pathology. Emerging genetic and pathological evidence suggests a mechanistic interplay between α-Syn and tau that amplifies their aggregation and accelerates neurodegeneration. In this study, we systematically investigated the temporal progression of tau pathology in a transgenic PD mouse model that overexpresses human wild-type (WT) α-Syn (hSyn mice). Prior work has shown that this model develops α-Syn pathology across key brain regions, including the substantia nigra, cortex, hippocampus, and striatum, accompanied by microglial activation and synaptic dysfunction. Using a combination of biochemical, biophysical, and immunological approaches, we demonstrate a progressive accumulation of hyperphosphorylated tau, as well as soluble and insoluble tau aggregates, in the brains of hSyn mice. Electron microscopy of insoluble fractions reveals abundant fibrillar structures, while mass spectrometry confirms that these fibrils consist of both α-Syn and tau. Notably, these pathologies are absent in WT littermates, suggesting that tau aggregation arises as a consequence of α-Syn overexpression rather than normal aging. Collectively, our findings establish a mechanistic link between α-Syn and tau aggregation, identifying tau as an active contributor to α-Syn-driven neurodegeneration. This study provides direct experimental evidence that tau co-pathology contributes to disease progression in synucleinopathies, underscoring the therapeutic potential of targeting pathological tau to mitigate neurodegeneration in PD, DLB, and related disorders.

Key findings

• Prior work has shown that this model develops α-Syn pathology across key brain regions, including the substantia nigra, cortex, hippocampus, and striatum, accompanied by microglial activation and synaptic dysfunction.
• Notably, these pathologies are absent in WT littermates, suggesting that tau aggregation arises as a consequence of α-Syn overexpression rather than normal aging.
• Collectively, our findings establish a mechanistic link between α-Syn and tau aggregation, identifying tau as an active contributor to α-Syn-driven neurodegeneration.

Study details

• Evidence strengthLow

Read the original

• DOI: 10.21203/rs.3.rs-8166445/v1
• PubMed: 41377958
• Original source →

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

@article{senapati2025-41377958,
  author  = {Senapati, Sudipta and Sciortino, Alessia and Samples, Madison and Shchankin, Nikita and Zhao, Yingxin and Montalbano, Mauro and Kayed, Rakez},
  title   = {{Human Wild-Type α-Synuclein Drives Progressive Tau Pathology in a Disease-Relevant Mouse Model of Synucleinopathy}},
  journal = {Research square},
  year    = {2025},
  doi     = {10.21203/rs.3.rs-8166445/v1},
  pmid    = {41377958},
  url     = {https://doi.org/10.21203/rs.3.rs-8166445/v1}
}

Related studies in Brain tissue and pathology

• Collusion of α-Synuclein and Aβ aggravating co-morbidities in a novel prion-type mouse model Molecular neurodegeneration · 2021-09-09 · usefulness score 41/100
• Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice The Journal of experimental medicine · 2012-04-16 · usefulness score 40/100
• Parenchymal and Dyshoric Fibrillar Amyloid Pathology in the rTg-D Rat Model of Cerebral Amyloid Angiopathy Type-2 American Journal Of Pathology · 2025-07-17 · usefulness score 35/100
• Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer's disease Molecular neurodegeneration · 2025-03-18 · usefulness score 68/100
• Amyloid-β, Tau Protein, α-Synuclein, TDP-43, and FUS in Mixed Pathology: And Intrinsic Disorder to Rule Them All International Journal of Molecular Sciences · 2026-04-20 · usefulness score 47/100
• Gut-induced alpha-Synuclein and Tau propagation initiate Parkinson's and Alzheimer's disease co-pathology and behavior impairments Neuron · 2024-09-05 · usefulness score 43/100

Similar studies

• Distinct α-synuclein strains differentially promote tau inclusions in neurons 2013 · Brain tissue and pathology
• Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies 2015 · Drug development
• Revisiting the grammar of Tau aggregation and pathology formation: how new insights from brain pathology are shaping how we study and target Tauopathies 2022 · Drug development
• Understanding Tau pathology: Insights from animal models 2025 · Drug development
• LRRK2, alpha-synuclein, and tau: partners in crime or unfortunate bystanders? 2019 · Prevention trials
• Tau and tauopathies 2016 · Disease mechanisms

More on Brain tissue and pathology

• A review that covers this ground NEURODEGENERATION. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein Science (New York, N.Y.) · 2015-08-01 · usefulness score 41/100
• Newest in this subject Inflammatory biomarker candidates in dementia with Lewy bodies: diagnostic classification, clinical associations, and survival Research Square · 2026-11-01 · Preprint — not yet peer-reviewed · usefulness score 16/100
• Newest in this subject TMEM106B C-Terminal fragment aggregation exacerbates α-synuclein and TDP-43 proteinopathy phenotypes bioRxiv · 2026-10-30 · Preprint — not yet peer-reviewed · usefulness score 16/100

See all studies in Brain tissue and pathology →